Europe Blood-based Biomaker For Sports Medicine Market Size & Outlook
Europe blood-based biomaker for sports medicine market, 2018-2030 (US$M)
Related Markets
Europe blood-based biomaker for sports medicine market highlights
- The Europe blood-based biomaker for sports medicine market generated a revenue of USD 179.2 million in 2023.
- The market is expected to grow at a CAGR of 8.2% from 2024 to 2030.
- In terms of segment, ck was the largest revenue generating type in 2023.
- CRP is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, Germany is expected to register the highest CAGR from 2024 to 2030.
Europe data book summary
| Market revenue in 2023 | USD 179.2 million |
| Market revenue in 2030 | USD 310.4 million |
| Growth rate | 8.2% (CAGR from 2023 to 2030) |
| Largest segment | Ck |
| Fastest growing segment | CRP |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CK, Myoglobin, Lactate, WBC, Urea, CRP, Lipid and Protein Hydroperoxides, IL-6 |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.9% of the global blood-based biomaker for sports medicine market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 259.9 million by 2030.
Ck was the largest segment with a revenue share of 18.02% in 2023. Horizon Databook has segmented the Europe blood-based biomaker for sports medicine market based on ck, myoglobin, lactate, wbc, urea, crp, lipid and protein hydroperoxides, il-6 covering the revenue growth of each sub-segment from 2018 to 2030.
Technological advancements and increased research in blood-based biomarkers are expected to significantly drive market growth in Europe. For instance, in October 2023, bioMérieux, announced the CE-marking of VIDAS TBI (GFAP, UCH-L1). This blood test aids in the assessment of patients with mild traumatic brain injury through the unique combination of two brain biomarkers.
Cutting-edge technologies have enhanced the sensitivity and accuracy of biomarkers, making them crucial tools for diagnosing and managing sports-related injuries. Ongoing research is uncovering new biomarkers and refining existing ones, which is expected to expand their applications in injury prevention and recovery monitoring.
In Europe, this technological progress and research focus are expected to propel market growth. Sports organizations and healthcare providers increasingly adopt these advanced biomarkers to improve athlete care and performance. The integration of these innovations is leading to more effective and personalized approaches to managing sports injuries, which is projected to fuel market demand. As the European sports medicine sector embraces these advancements, the market is expected to witness significant growth over the forecast period.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blood-based Biomaker for Sports Medicine Market Scope
Blood-based Biomaker for Sports Medicine Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Europe blood-based biomaker for sports medicine market size, by country, 2018-2030 (US$M)
Europe Blood-based Biomaker for Sports Medicine Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
